

GENERAL COUNTERDRUG INTELLIGENCE PLAN (GCIP) POLICY REVIEW

May 20, 2002

BACKGROUND:

In February 2000, then-President Clinton and eight cabinet level officials approved the General Counterdrug Intelligence Plan (GCIP) which established a national counterdrug intelligence architecture and long range agenda to enhance drug intelligence coordination and support to both policy and operational consumers. Over the intervening two years, significant progress has been made in implementing both the letter and spirit of the GCIP. About 40% of the 73 recommendations ("action items") identified in the GCIP have been completed and substantial progress has been made on an additional 30%.

In January 2002, the Director, Office of National Drug Control Policy (ONDCP) initiated a series of drug policy reviews to serve as the basis for developing the comprehensive drug control strategy and program for the Bush Administration. One element of this comprehensive effort was a review of the General Counterdrug Intelligence Plan. Focus of this review was to determine if the process is achieving its objectives and continues to be supported by the participating departments/agencies, and if adjustments need to be made. The review focused on Section A – National Counterdrug Intelligence Coordination, which prescribes the overall oversight and coordination structure for implementing the GCIP.

The GCIP review process was initiated on February 27, 2002, with an interagency meeting hosted by the Director, ONDCP. Representatives from each of the 13 departments and agencies that serve on the Counterdrug Intelligence Coordinating Group (CDICG) participated in the review.

SUMMARY OF GCIP MODIFICATIONS

This section addresses changes of individual elements of Section A of the GCIP. Elements/requirements not specifically changed by this document remain valid.

Section II: The President's Council on Counter-Narcotics

This section of the GCIP identified the President's Council on Counter-Narcotics (PCCN) and its subordinate body, the Counterdrug Intelligence Executive Committee, as the highest level body for overseeing implementation of the GCIP and resolving significant interagency drug intelligence issues.

The Director, ONDCP will accept unresolved issues submitted by the Counterdrug Intelligence Coordinating Group (CDICG) and prepare those issues for

resolution by the appropriate principals. It is expected that there will be few issues that cannot be resolved by the CDICG members.

Section III: Counterdrug Interagency Policy and Program Coordination

This section identifies a number of interdepartmental bodies that have policy development and operational coordination responsibilities and that can submit “cross-jurisdictional” drug intelligence requirements/issues to the CDICG for attention and/or resolution. “Cross-jurisdictional” refers to issues that affect or involve both the law enforcement community and the Foreign Intelligence Community, or, within the law enforcement community, issues that affect more than one department/agency and/or federal, state, and local entities.

The Counter-Narcotics Interagency Working Group (CN-IWG) has been replaced by the Counterdrug Issues Sub-Group of the Policy Coordinating Committee on International Organized Crime.

The Southern Frontiers Committee previously chaired by the Attorney General has been discontinued.

If additional drug law enforcement or drug related national security coordinating entities are established, the CDICG will ensure proper links are established.

Section IV: Counterdrug Intelligence Coordinating Group (CDICG)

This section identifies mission, functions, leadership, and membership of the Counterdrug Intelligence Coordinating Group and the Counterdrug Intelligence Executive Secretariat (CDX). In essence, the CDICG members are senior department and agency officials who represent their principals and who have the ability to advocate for GCIP issues within their department/agency policy and budget structures.

Full membership in the CDICG will remain the same except for the addition of the Office of Homeland Security as a non-voting member for coordination of counterdrug intelligence matters. The CDICG is authorized to invite additional entities to participate as observers. Including other, non-drug specific entities as observers will materially facilitate broader coordination but not dilute the focus on counterdrug intelligence issues.

Each department/agency will designate as its representative to the CDICG a senior official who has the ability to advocate effectively for GCIP/CDICG issues, including budget support, both within the department/agency and the interagency.

The CDICG will continue to be led by co-chairs from the Federal law enforcement community and the Foreign Intelligence Community. Tenure of the co-chairs should be limited to two years unless the selecting authorities determine a change is not appropriate.

The CDICG will continue to carry out all the functions enumerated in the GCIP. In submitting its semi-annual report to the principals, the CDICG will ensure that the report not only cites accomplishments but also identifies new issues or, if necessary, old issues that require resolution.

The CDICG has established three advisory/support entities to help it carry out its responsibilities: a State and Local Law Enforcement Advisory Board (SLLEAB); a Systems Policy Review Group (SPRG); and a Training Advisory Council (TAC). Each of these groups will continue.

The CDICG will conduct a complete review of the original 73 GCIP action items and existing component referrals. The review should result in a clear delineation of those action items that will be accorded the highest priority for completion/implementation, those that should be pursued at more routine pace, and those that are no longer viable and should be discontinued. For those high priority items that are to be emphasized, the CDX will develop an implementation plan that describes what is to be done, what the costs will be, and what individual department/agency responsibilities will be. This plan should be carefully considered when the CDICG validates the proposed action items.

Section V: Counterdrug Intelligence Executive Secretariat

The Counterdrug Intelligence Executive Secretariat (CDX) will continue as the full-time interagency staff supporting the CDICG and to carry out the functions enumerated in the GCIP and as directed by the CDICG membership.

Funding for the CDX will continue to be requested through the Office of National Drug Control Policy (ONDCP) appropriations process. The Department of Justice will continue to administer the funds and provide administrative support to the CDX/CDICG. The annual CDX/CDICG spending plan will be approved by the full CDICG and any changes to the spending plan (reprogramming) in excess of \$100,000 must be specifically approved by the full CDICG and the ONDCP. Funding for activities other than administration will be for those activities that directly support the highest priority GCIP implementation efforts that are capable of execution. Funds will not be used to supplant individual department/agency funding responsibilities. Funding for prototype initiatives must be directly tied to a business plan or development concept that is sufficiently definitive to clearly identify follow-on responsibilities/obligations of participating departments/agencies.

The CDX will continue to be located in its current facilities and should maintain a staff of approximately 10 fulltime detailees and an administrative staff of approximately 5, including the Director and Deputy Director. Departments/agencies will contribute additional part-time detailees to assist CDX staff in carrying out specific tasks identified by the CDICG. CDX will ensure that its facilities, including space and technical capabilities, are appropriate to the adjusted staff size. Reductions in facilities overhead should be reflected in the FY03 spending plan.

At least through FY03, ONDCP funds can be used to reimburse fulltime detailees from participating agencies. On a case-by-case basis, consideration can be given to reimbursement for a detailee assigned for at least 50% of the time. The specific number of reimbursements will depend on the availability of funds and negotiations between the CDICG/CDX and the individual agencies.